These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 10607684)

  • 1. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
    Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
    Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
    Nishi J; Maruyama I
    Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease.
    Sato Y; Kojima M; Takata K; Morito T; Asaoku H; Takeuchi T; Mizobuchi K; Fujihara M; Kuraoka K; Nakai T; Ichimura K; Tanaka T; Tamura M; Nishikawa Y; Yoshino T
    Mod Pathol; 2009 Apr; 22(4):589-99. PubMed ID: 19270642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases.
    Lajoie G; Kumar S; Min KW; Silva FG
    Am J Surg Pathol; 1995 Sep; 19(9):1021-8. PubMed ID: 7661275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic multicentric Castleman's disease: a systematic literature review.
    Liu AY; Nabel CS; Finkelman BS; Ruth JR; Kurzrock R; van Rhee F; Krymskaya VP; Kelleher D; Rubenstein AH; Fajgenbaum DC
    Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
    Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
    BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
    Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.
    Beck JT; Hsu SM; Wijdenes J; Bataille R; Klein B; Vesole D; Hayden K; Jagannath S; Barlogie B
    N Engl J Med; 1994 Mar; 330(9):602-5. PubMed ID: 8302342
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
    Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
    Ohsugi Y; Tsuchimoto N
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
    [No Abstract]   [Full Text] [Related]  

  • 12. Castleman's disease: from basic mechanisms to molecular therapeutics.
    El-Osta HE; Kurzrock R
    Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.
    Ikeda S; Chisuwa H; Kawasaki S; Ozawa J; Hoshii Y; Yokota T; Aoi T
    J Clin Pathol; 1997 Nov; 50(11):965-7. PubMed ID: 9462253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.
    Kinney MC; Hummell DS; Villiger PM; Hourigan A; Rollins-Smith L; Glick AD; Lawton AR
    J Clin Immunol; 1994 Nov; 14(6):382-90. PubMed ID: 7883866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
    Nishimoto N; Kishimoto T; Yoshizaki K
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i21-7. PubMed ID: 11053081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Transitional type of Castleman's disease manifested as the POEMS syndrome].
    Tomić I; Plavec G; Tasić O; Ristanović A; Cvijanović V
    Vojnosanit Pregl; 2004; 61(4):439-44. PubMed ID: 15552541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman's disease: a single medical center study in Tunisia.
    Chabchoub I; Salah RB; Kallel R; Snoussi M; Frikha F; Marzouk S; Boudawara TS; Bahloul Z
    Rom J Intern Med; 2024 Mar; 62(1):20-32. PubMed ID: 37948573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Clinical Characteristics, Pathological Changes and Changes of Interleukin-6 (IL-6) and C-Reactive Protein (CRP) in Children with Castleman's Disease.
    Hu C; Zou Y; Pan J; Yang J; Yang T; Tan T; Li J
    Med Sci Monit; 2020 Aug; 26():e924783. PubMed ID: 32873770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.
    Yoshizaki K; Matsuda T; Nishimoto N; Kuritani T; Taeho L; Aozasa K; Nakahata T; Kawai H; Tagoh H; Komori T
    Blood; 1989 Sep; 74(4):1360-7. PubMed ID: 2788466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of long term administration of humanized anti-interleukin-6 receptor antibody (tocilizumab) for multicentric Castleman's disease with pulmonary involvement].
    Akahane D; Kimura Y; Sumi M; Sashida G; Gotoh A; Miyazawa K; Ohyashiki K
    Rinsho Ketsueki; 2006 Aug; 47(8):748-52. PubMed ID: 16986713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.